Moderna (NASDAQ:MRNA) Price Target Raised to $195.00

Moderna (NASDAQ:MRNA) had its target price increased by The Goldman Sachs Group from $137.00 to $195.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other analysts also recently weighed in on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $130.00 target price on shares of Moderna in a research report on Wednesday, August 19th. Deutsche Bank assumed coverage on shares of Moderna in a research report on Friday, August 28th. They set a “hold” rating and a $125.00 price target for the company. William Blair lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 27th. UBS Group restated a “neutral” rating on shares of Moderna in a report on Tuesday, September 22nd. Finally, Bank of America raised their target price on shares of Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, Moderna has an average rating of “Hold” and an average price target of $113.75.

Moderna Trading Down 0.9%

NASDAQ MRNA opened at $248.69 on Monday. The firm has a market capitalization of $100.63 billion, a PE ratio of -35.03 and a beta of 1.16. The stock’s 50 day moving average is $198.57 and its 200 day moving average is $94.60. Moderna has a twelve month low of $22.28 and a twelve month high of $280.80. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.51) earnings per share. Research analysts forecast that Moderna will post -5.34 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In other Moderna news, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the transaction, the president owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This represents a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 197,251 shares of company stock worth $33,875,904 over the last quarter. 10.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRNA. Ethic Inc. grew its stake in shares of Moderna by 23.6% during the 3rd quarter. Ethic Inc. now owns 19,394 shares of the company’s stock valued at $3,735,000 after purchasing an additional 3,700 shares during the period. Merck & Co. Inc. bought a new position in shares of Moderna in the 2nd quarter worth approximately $161,642,545. Bank of New York Mellon Corp bought a new position in shares of Moderna in the 2nd quarter worth approximately $119,168,000. Contravisory Investment Management Inc. boosted its holdings in shares of Moderna by 1,387.6% in the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock worth $1,696,000 after buying an additional 22,590 shares during the last quarter. Finally, TD Waterhouse Canada Inc. grew its position in Moderna by 2,042.6% during the third quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock valued at $13,722,000 after buying an additional 69,203 shares during the period. Institutional investors own 75.33% of the company’s stock.

Key Headlines Impacting Moderna

These are some of the MRNA headlines that stood out recently:

• Positive Sentiment: A publication in JAMA Network Open reported real-world comparative effectiveness data for mNEXSPIKE in adults aged 65 and older, based on more than 294,000 U.S. veterans. The findings could support the vaccine’s value in an important older-adult population. mNEXSPIKE real-world effectiveness publication
• Neutral Sentiment: Brookline Capital Markets kept a Buy rating and raised its 2026–2028 EPS estimates, although it still projects losses in those years. Moderna analyst estimate revisions
• Negative Sentiment: Brookline lowered its fourth-quarter 2026 EPS estimate to a loss of $2.87 per share from a projected loss of $2.09, signaling weaker near-term earnings expectations despite its improved full-year and later-year forecasts. Moderna analyst estimate revisions

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.